Abstract:Globally, the continuous spread and evolution of SARS-CoV-2, along with its variants, profoundly impact human well-being, health, security, and the growth of socio-economic. In the field of development of drugs against COVID-19, the main protease (Mpro) is a critical target as it plays a core role in the lifecycle of SARS-CoV-2. Bofutrelvir acts as a potent inhibitor of SARS-CoV-2 Mpro, demonstrating high efficacy and broad-spectrum antiviral activity. Compared to therapies that require pharmacokinetic boosters, such as ritonavir, the monotherapy approach of Bofutrelvir reduces the risk of potential drug interactions, making it suitable for a wider patient population. However, further studies on the potency and mechanism of inhibition of Bofutrelvir against the Mpro of COVID-19 and its variants, together with other coronaviruses, are needed to prepare for the possibility of a possible re-emerging threat from an analogous virus in the future. Here, we reveal the effective inhibition of Bofutrelvir against the Mpro of SARS-CoV-2, SARS-CoV, and HCoV-229E through FRET and crystallographic analysis. Furthermore, the inhibitory mechanisms of Bofutrelvir against two SARS-CoV-2 Mpro mutants (G15S and K90R) were also elucidated through FRET and crystallographic studies. Through detailed analysis and comparison of these crystal structures, we identified crucial structural determinants of inhibition and elucidated the binding mode of Bofutrelvir to Mpros from different coronaviruses. These findings are hopeful to accelerate the development of safer and more potent inhibitors against the Mpro of coronavirus, and to provide important references for the prevention and treatment of similar viruses that may emerge in the future.

Structural basis for the inhibition of coronaviral main proteases by PF-00835231

Structures of Two Coronavirus Main Proteases: Implications for Substrate Binding and Antiviral Drug Design.

Structural Basis of Main Proteases of Coronavirus Bound to Drug Candidate PF-07304814.

Crystal structures of main protease (M pro ) mutants of SARS-CoV-2 variants bound to PF-07304814

Crystal structures of main protease (Mpro) mutants of SARS-CoV-2 variants bound to PF-07304814

Structural basis of main proteases of HCoV-229E bound to inhibitor PF-07304814 and PF-07321332

Structural Basis for the Inhibition of Coronaviral Main Proteases by a Benzothiazole-Based Inhibitor

Crystal Structure of SARS-CoV-2 Main Protease (mpro) Mutants in Complex with the Non-Covalent Inhibitor CCF0058981.

Structural Basis for coronaviral main proteases Inhibition by a 3CL Protease Inhibitor- GC376

Structural basis of main proteases of coronavirus bound to Bofutrelvir

Crystal structures of coronaviral main proteases in complex with the non-covalent inhibitor X77

Structural Basis for Coronaviral Main Proteases Inhibition by the 3clpro Inhibitor GC376.

Structural Basis of the Main Proteases of Coronavirus Bound to Drug Candidate PF-07321332

Crystal Structures of Main Proteases of SARS-CoV-2 Variants Bound to a Benzothiazole-Based Inhibitor

Binding Mechanism of Inhibitors to SARS-CoV-2 Main Protease Deciphered by Multiple Replica Molecular Dynamics Simulations.

Structural and mechanistic insights into Main protease (Mpro) dimer interface destabilization inhibitor: Unveiling new therapeutic avenues against SARS-CoV-2

Design of wide-spectrum inhibitors targeting coronavirus main proteases

Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease

Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M pro and cathepsin L

Discovery and structure-activity relationship studies of novel α-ketoamide derivatives targeting the SARS-CoV-2 main protease

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease